Lupin receives USFDA nod to market Tamiflu capsules to treat influenza
Oseltamivir phosphate capsules are indicated for the treatment of influenza
 "Lupin")
An employee of Lupin Limited works at a reception at their headquarters in Mumbai
Drug major Lupin on Wednesday said it has received approval from the US Food and Drug Administration (USFDA) to market a generic version of Tamiflu capsules, used in treating influenza.
The company has received final approval from the US drug regulator to market oseltamivir phosphate capsules, a generic version of Hoffman-La Roche Inc's Tamiflu capsules in strengths of 30 mg, 45 mg, and 75 mg, Lupin said in a statement.
Oseltamivir phosphate capsules are indicated for the treatment of influenza.
As per IMS MAT October 2017 data, the capsules clocked annual sales of around $467.8 million in the US market.
Shares of Lupin closed 0.46 per cent up at Rs 925.05 on the BSE.
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jan 10 2018 | 5:43 PM IST